Lakewood-Amedex Biotherapeutics closed at $0.20 on Nov 3, up 5.41%, 91.2% below its highest close since Sep 11. Volume of 878.1K shares was 0.20× its 20-day average (below normal).
Split-adjusted performance: -77.2% over one month.
Short interest was 90.0K shares at the Oct 15 settlement, down 31.1% from the prior report (1.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LABTLakewood-Amedex Biotherapeutics | $0.1950 | +5.41% | — | — | — | — | $462.1K | |
| DCOYDecoy Therapeutics | $1.11 | +7.25% | −81.0% | — | −1042.8% | — | $727.3K | Compare |
| NXTSNexentis Technologies | $0.5690 | +7.08% | — | — | — | — | $826.9K | Compare |
| VBIOValion Bio | $0.5309 | 0.00% | — | — | — | — | $1.1M | Compare |
| MTNBMatinas BioPharma Holdings | $1.14 | −11.63% | −88.3% | — | — | — | $1.1M | Compare |
| JAGXJaguar Health | $0.5575 | −36.94% | −97.5% | −58.9% | −1036.8% | — | $1.3M | Compare |
| ARTLArtelo Biosciences | $2.40 | +10.60% | −91.3% | — | — | — | $1.3M | Compare |
| GOVXGeoVax Labs, Inc. New | $0.1641 | +0.67% | −88.4% | −100.0% | — | — | $1.5M | Compare |
| ELABPMGC Holdings | $1.94 | −7.62% | −91.2% | — | −225.1% | — | $1.6M | Compare |
No recent articles focused on Lakewood-Amedex Biotherapeutics.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
